索磷布韦为基础的无干扰素直接作用抗病毒治疗方案用于慢性丙型肝炎病毒感染的心脏移植受者。
Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus Infection.
机构信息
Department of Internal Medicine, National Taiwan University Hospital, Taipei.
Hepatitis Research Center, National Taiwan University Hospital, Taipei.
出版信息
Clin Infect Dis. 2018 Jan 6;66(2):289-292. doi: 10.1093/cid/cix787.
PMID:29020359
Abstract
We assessed the effectiveness and safety of sofosbuvir (SOF) combined with ledipasvir (LDV) or daclatasvir (DCV) in 12 heart transplant recipients with chronic hepatitis C virus (HCV). The sustained virologic response (SVR12) rate was 100% [95% confidence interval [CI]: 75.8%-100%]. All patients tolerated treatment well without interruption, death, or serious adverse events.
摘要
我们评估了索磷布韦（SOF）联合利巴韦林（LDV）或达卡他韦（DCV）在 12 例心脏移植受者慢性丙型肝炎病毒（HCV）中的疗效和安全性。持续病毒学应答（SVR12）率为 100%[95%置信区间（CI）：75.8%-100%]。所有患者均耐受治疗，无中断、死亡或严重不良事件。
Zotero 插件